PP090—The 3.5-year mortality impact of drugs in secondary prevention of myocardial infarction in real-life (interim analysis of the eole cohort)

Few studies have assessed the real-life impact of secondary prevention drugs on all-cause mortality postmyocardial infarction (MI), especially in countries with low incidence of MI. The objective of this interim analysis after 3.5-year of follow-up was to assess the real-life all-cause mortality impact of drugs reimbursed for MI secondary prevention in France: acetylsalicylic acid (ASA), antiplatelet agents (APA), beta-blockers (ß-), angiotensin-converting enzyme inhibitors (ACEI), statins, and omega-3 supplementation (Om3)